Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11839058 | 1.00 | ADRB1 (0.44) | ADRB1OPRD1HRH4SLC6A4SLC6A2 | |
| SCHEMBL31429820 | 0.86 | ATM (0.48) | SLC6A4SLC6A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7288770 | 0.85 | MEN1 (0.37) | ADRB1OPRD1HRH4SLC6A4MEN1 | |
| SCHEMBL7432917 | 0.84 | ATM (0.47) | SLC6A4SLC6A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1080006 | 0.84 | ADRB1 (0.48) | ADRB1OPRD1HRH4SLC6A4SLC6A2 | |
| SCHEMBL7435488 | 0.82 | CYP3A4 (0.36) | CYP3A4CYP2D6CYP2C9CHRM2CHRM1 | |
| SCHEMBL7289698 | 0.82 | RXFP1 (0.44) | ADRB1OPRD1SLC6A4SLC6A2CYP1A2 | |
| SCHEMBL11847697 | 0.81 | HTR3E (0.43) | ADRB1OPRD1SLC6A4SLC6A2HTR1A | |
| SCHEMBL7289950 | 0.78 | SLC6A2 (0.47) | OPRD1SLC6A4SLC6A2CYP3A4CYP2D6 | |
| SCHEMBL7291885 | 0.77 | HTR2C (0.38) | ADRB1OPRD1HRH4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103570645-A | Method for preparing N-(2,6-dimethyl phenyl)-2-(1-piperazine)acetamide | SHANGHAI DESANO CHEMICAL PHARM | 2014-02-12 | — | — | CN | claimed |
| US-20110223213-A1 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | claimed |
| EP-2356097-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group PTC ehf. (IS) | 2011-08-17 | — | — | EP | claimed |
| WO-2010043976-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-04-22 | — | — | WO | claimed |
| US-3959281-A | CORONARY DILATORS | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | claimed |
| CN-103570645-A | Method for preparing N-(2,6-dimethyl phenyl)-2-(1-piperazine)acetamide | SHANGHAI DESANO CHEMICAL PHARM | 2014-02-12 | — | — | CN | disclosed |
| EP-2586774-A1 | METHOD FOR PREPARATION OF RANOLAZINE | Shanghai Kuoikee Laboratories Co., Ltd (CN) | 2013-05-01 | — | — | EP | disclosed |
| US-20130090475-A1 | Process for the Preparation of Ranolazine | ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-04-11 | — | — | US | disclosed |
| US-20110223213-A1 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | disclosed |
| EP-2356097-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group PTC ehf. (IS) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010043976-A2 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010029436-A2 | NOVEL SOLID STATE FORMS OF RANOLAZINE SALTS | ACTAVIS GROUP PTC EHF (IS) | 2010-03-18 | — | — | WO | disclosed |
| EP-0862566-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997016440-A1 | 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-09 | — | — | WO | disclosed |
| US-4567264-A | ADRENERGIC BLOCKING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4558129-A | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade | SYNTEX (U.S.A.) INC. (US) | 1985-12-10 | — | — | US | disclosed |
| EP-0126449-A1 | Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry | SYNTEX (U.S.A.) INC. (US) | 1984-11-28 | — | — | EP | disclosed |
| US-3959281-A | CORONARY DILATORS | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223213-A1 | HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | REN, ADRB3, RAN | ADRB1 8/4885OPRD1 83/4885HRH4 211/4885 |
| US-20130090475-A1 | Process for the Preparation of Ranolazine | RANBP1, RANBP2, RAN | ADRB1 492/4885OPRD1 300/4885HRH4 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.